Pediatrix Medical Group 미래 성장

Future 기준 확인 3/6

Pediatrix Medical Group (는) 각각 연간 95.2% 및 0.01% 수익과 수익이 증가할 것으로 예상됩니다. EPS는 연간 83.1% 만큼 성장할 것으로 예상됩니다. 자기자본이익률은 3년 후 15.2% 로 예상됩니다.

주요 정보

95.2%

수익 성장률

83.1%

EPS 성장률

Healthcare 수익 성장	20.8%
매출 성장률	0.006%
향후 자기자본 수익률	15.2%
애널리스트 커버리지	Good
마지막 업데이트	16 Dec 2024

최근 미래 성장 업데이트

Recent updates

Pediatrix Medical Group: The Business Is Turning

Nov 18

Pediatrix Medical Group, Inc. (NYSE:MD) Shares Fly 27% But Investors Aren't Buying For Growth

Nov 06

Here's Why Pediatrix Medical Group (NYSE:MD) Has A Meaningful Debt Burden

Oct 19

We Like These Underlying Return On Capital Trends At Pediatrix Medical Group (NYSE:MD)

Sep 28

Improved Revenues Required Before Pediatrix Medical Group, Inc. (NYSE:MD) Stock's 32% Jump Looks Justified

Aug 07

Pediatrix Medical Group, Inc.'s (NYSE:MD) Intrinsic Value Is Potentially 100% Above Its Share Price

Jan 10

Pediatrix Medical Group, Inc.'s (NYSE:MD) Earnings Are Not Doing Enough For Some Investors

Dec 25

Is Pediatrix Medical Group (NYSE:MD) A Risky Investment?

Nov 14

Is It Time To Consider Buying Pediatrix Medical Group, Inc. (NYSE:MD)?

Oct 13

Does Pediatrix Medical Group (NYSE:MD) Have A Healthy Balance Sheet?

Aug 09

Pediatrix: Unable To Deploy Capital Tied Up In Cash Conversion Cycle, Reiterate Hold

Aug 08

At US$14.21, Is Pediatrix Medical Group, Inc. (NYSE:MD) Worth Looking At Closely?

Jul 03

The Returns At Pediatrix Medical Group (NYSE:MD) Aren't Growing

Jun 08

Pediatrix Medical Group (NYSE:MD) Has A Somewhat Strained Balance Sheet

Apr 26

Is Now An Opportune Moment To Examine Pediatrix Medical Group, Inc. (NYSE:MD)?

Feb 20

Pediatrix Medical Group Q4 2022 Earnings Preview

Feb 16

Is Pediatrix Medical Group (NYSE:MD) A Risky Investment?

Jan 12

Pediatrix: RCM Overhang Now Too Heavy, Revise To Hold

Dec 22

Return Trends At Pediatrix Medical Group (NYSE:MD) Aren't Appealing

Dec 20

Pediatrix appoints James Swift as chief executive officer

Dec 15

Why Pediatrix Medical Group, Inc. (NYSE:MD) Could Be Worth Watching

Nov 05

Pediatrix Medical Group GAAP EPS of $0.37 misses by $0.11, revenue of $489.92M misses by $21.54M

Nov 03

Pediatrix: These 5 Graphs Suggest It's A Buy

Sep 29

Here's Why Pediatrix Medical Group (NYSE:MD) Can Manage Its Debt Responsibly

Sep 13

Here's What To Make Of Pediatrix Medical Group's (NYSE:MD) Decelerating Rates Of Return

Aug 29

Why Pediatrix Medical Group, Inc. (NYSE:MD) Could Be Worth Watching

Jul 27

Pediatrix: Seeking 46% Return Objective As Speculative Buy

Jul 14

MEDNAX, Inc. (NYSE:MD) Shares Could Be 47% Below Their Intrinsic Value Estimate

Jun 24

MEDNAX (NYSE:MD) Has A Pretty Healthy Balance Sheet

May 25

Return Trends At MEDNAX (NYSE:MD) Aren't Appealing

Apr 20

MEDNAX, Inc.'s (NYSE:MD) Intrinsic Value Is Potentially 96% Above Its Share Price

Mar 08

MEDNAX (NYSE:MD) Seems To Use Debt Quite Sensibly

Feb 15

수익 및 매출 성장 예측

NYSE:MD - 애널리스트의 미래 추정치 및 과거 재무 데이터 (USD Millions )
날짜	수익	수익	잉여 현금 흐름	작전 현금	평균 애널리스트 수
12/31/2026	2,001	121	N/A	N/A	6
12/31/2025	1,944	115	131	162	8
12/31/2024	1,997	-17	102	136	8
9/30/2024	2,007	-254	115	143	N/A
6/30/2024	2,002	-252	100	131	N/A
3/31/2024	1,999	-71	81	113	N/A
12/31/2023	1,995	-60	104	137	N/A
9/30/2023	2,012	88	133	167	N/A
6/30/2023	1,995	95	139	170	N/A
3/31/2023	1,981	98	134	164	N/A
12/31/2022	1,972	63	137	167	N/A
9/30/2022	1,957	79	89	112	N/A
6/30/2022	1,960	82	63	90	N/A
3/31/2022	1,947	82	31	61	N/A
12/31/2021	1,911	108	44	77	N/A
9/30/2021	1,829	72	-15	21	N/A
6/30/2021	1,797	38	99	129	N/A
3/31/2021	1,739	14	236	264	N/A
12/31/2020	1,734	-10	176	205	N/A
9/30/2020	1,776	-4	326	352	N/A
6/30/2020	1,770	11	321	341	N/A
3/31/2020	1,678	1	261	284	N/A
12/31/2019	1,780	42	338	358	N/A
9/30/2019	2,210	94	331	351	N/A
6/30/2019	2,603	143	292	320	N/A
3/31/2019	3,145	221	296	324	N/A
12/31/2018	1,723	122	297	314	N/A
9/30/2018	3,477	333	303	346	N/A
6/30/2018	3,497	337	N/A	417	N/A
3/31/2018	3,475	326	N/A	420	N/A
12/31/2017	3,253	305	N/A	498	N/A
9/30/2017	3,378	262	N/A	447	N/A
6/30/2017	3,337	293	N/A	443	N/A
3/31/2017	3,266	312	N/A	455	N/A
12/31/2016	3,183	325	N/A	444	N/A
9/30/2016	3,094	340	N/A	417	N/A
6/30/2016	2,988	334	N/A	393	N/A
3/31/2016	2,893	336	N/A	389	N/A
12/31/2015	2,780	336	N/A	369	N/A
9/30/2015	2,689	332	N/A	443	N/A
6/30/2015	2,593	327	N/A	431	N/A
3/31/2015	2,512	322	N/A	419	N/A
12/31/2014	2,439	317	N/A	423	N/A
9/30/2014	2,356	308	N/A	383	N/A
6/30/2014	2,284	299	N/A	382	N/A
3/31/2014	2,218	289	N/A	374	N/A
12/31/2013	2,154	281	N/A	405	N/A

애널리스트 미래 성장 예측

수입 대 저축률: MD 은 향후 3년 동안 수익을 낼 것으로 예상되며, 이는 절약률( 2.6% )보다 빠른 성장으로 간주됩니다.

수익 vs 시장: MD (는) 향후 3년 동안 평균 시장 성장보다 높은 수익을 올릴 것으로 예상됩니다.

고성장 수익: MD 향후 3년 내에 수익을 낼 것으로 예상됩니다.

수익 대 시장: MD 의 수익(연간 0.01% ) US 시장( 9.1% 보다 느리게 성장할 것으로 예상됩니다. 9.1% 연간).

고성장 수익: MD 의 수익(연간 0.01% )은 연간 20% 보다 느리게 증가할 것으로 예상됩니다.

주당 순이익 성장 예측

미래 자기자본 수익률

미래 ROE: MD 의 자본 수익률은 3년 내에 최저 수준이 될 것으로 예상됩니다( 15.2 %).

성장 기업 발견

기업 분석 및 재무 데이터 현황

데이터	마지막 업데이트(UTC 시간)
기업 분석	2024/12/22 15:29
장 마감 주가	2024/12/20 00:00
수익	2024/09/30
연간 수익	2023/12/31

데이터 소스

기업 분석에 사용된 데이터는 S&P Global Market Intelligence LLC의 데이터입니다. 이 보고서를 생성하기 위해 분석 모델에 사용된 데이터는 다음과 같습니다. 데이터는 정규화되어 있으므로 소스가 제공되기까지 지연이 발생할 수 있습니다.

패키지	데이터	기간	미국 소스 예시 ^*
회사 재무	10년	손익 계산서 현금 흐름표 대차 대조표	SEC 양식 10-K SEC 양식 10-Q
애널리스트 컨센서스 추정치	+3년	재무 예측 애널리스트 목표가	애널리스트 연구 보고서 Blue Matrix
시장 가격	30년	주식 가격 배당금, 분할 및 액션	ICE 시장 데이터 SEC 양식 S-1
소유권	10년	최대 주주 내부자 거래	SEC 양식 4 SEC 양식 13D
관리	10년	리더십 팀 이사회	SEC 양식 10-K SEC 양식 DEF 14A
주요 개발 사항	10년	회사 공지 사항	SEC 양식 8-K

* 미국 증권의 경우, 미국 외 지역의 규제 양식 및 출처가 사용된 예입니다.

명시되지 않는 한 모든 재무 데이터는 1년을 기준으로 하지만 분기별로 업데이트됩니다. 이를 후행 12개월(TTM) 또는 최근 12개월(LTM) 데이터라고 합니다. 여기에서 자세히 알아보세요.

분석 모델 및 눈송이

이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 Github 페이지에서 확인할 수 있으며, 보고서 사용 방법에 대한 가이드와 튜토리얼도 유튜브에서 확인할 수 있습니다.

Simply 월스트리트 분석 모델을 설계하고 구축한 세계적인 수준의 팀에 대해 알아보세요.

산업 및 부문 메트릭

업계 및 섹션 지표는 Simply Wall St에서 6시간마다 계산되며, 자세한 내용은 확인할 수 있습니다.

애널리스트 출처

Pediatrix Medical Group, Inc. 32 애널리스트 중 8 애널리스트가 보고서의 입력 자료로 사용된 매출 또는 수익 추정치를 제출했습니다. 애널리스트의 제출 자료는 하루 종일 업데이트됩니다.

분석가	교육기관
David Toung	Argus Research Company
Matthew Gillmor	Baird
James Kumpel	BB&T Capital Markets

Pediatrix Medical Group 미래 성장

Future 기준 확인 3/6

주요 정보

최근 미래 성장 업데이트

Price target increased by 9.4% to US$11.58

Price target increased by 11% to US$9.14

Price target decreased by 7.3% to US$8.21

Price target decreased by 8.0% to US$9.07

Consensus EPS estimates fall by 21%

Price target decreased by 12% to US$14.80

Recent updates

Pediatrix Medical Group: The Business Is Turning

Chair recently sold US$424k worth of stock

Chair notifies of intention to sell stock

Pediatrix Medical Group, Inc. (NYSE:MD) Shares Fly 27% But Investors Aren't Buying For Growth

Third quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Pediatrix Medical Group, Inc. Provides Goodwill and Long-Lived Asset Impairments Guidance for the Year Ending December 31, 2024

Here's Why Pediatrix Medical Group (NYSE:MD) Has A Meaningful Debt Burden

Pediatrix Medical Group, Inc. to Report Q3, 2024 Results on Nov 01, 2024

Price target increased by 9.4% to US$11.58

We Like These Underlying Return On Capital Trends At Pediatrix Medical Group (NYSE:MD)

CEO & Director recently sold US$120k worth of stock

CEO & Director notifies of intention to sell stock

Executive VP & CFO recently sold US$504k worth of stock

Executive VP & CFO notifies of intention to sell stock

Price target increased by 11% to US$9.14

New minor risk - Shareholder dilution

Second quarter 2024 earnings: EPS misses analyst expectations

Improved Revenues Required Before Pediatrix Medical Group, Inc. (NYSE:MD) Stock's 32% Jump Looks Justified

Pediatrix Medical Group, Inc. to Report Q2, 2024 Results on Aug 06, 2024

Price target decreased by 7.3% to US$8.21

Does Pediatrix Medical Group (NYSE:MD) Have A Healthy Balance Sheet?

Pediatrix Medical Group (NYSE:MD) Has Some Way To Go To Become A Multi-Bagger

New major risk - Financial position

First quarter 2024 earnings: EPS and revenues miss analyst expectations

Pediatrix Medical Group, Inc. to Report Q1, 2024 Results on May 07, 2024

Pediatrix Medical Group, Inc., Annual General Meeting, May 09, 2024

Pediatrix Medical Group, Inc.'s (NYSE:MD) Price Is Right But Growth Is Lacking

Price target decreased by 8.0% to US$9.07

Full year 2023 earnings: EPS and revenues miss analyst expectations

Pediatrix Medical Group, Inc. to Report Q4, 2023 Results on Feb 20, 2024

Pediatrix Medical Group, Inc.'s (NYSE:MD) Intrinsic Value Is Potentially 100% Above Its Share Price

Pediatrix Medical Group, Inc.'s (NYSE:MD) Earnings Are Not Doing Enough For Some Investors

Is Pediatrix Medical Group (NYSE:MD) A Risky Investment?

Consensus EPS estimates fall by 21%

New major risk - Revenue and earnings growth

Third quarter 2023 earnings: EPS misses analyst expectations

Pediatrix Medical Group, Inc. to Report Q3, 2023 Results on Nov 02, 2023

Is It Time To Consider Buying Pediatrix Medical Group, Inc. (NYSE:MD)?

Price target decreased by 12% to US$14.80

Does Pediatrix Medical Group (NYSE:MD) Have A Healthy Balance Sheet?

Pediatrix: Unable To Deploy Capital Tied Up In Cash Conversion Cycle, Reiterate Hold

Second quarter 2023 earnings: EPS misses analyst expectations

At US$14.21, Is Pediatrix Medical Group, Inc. (NYSE:MD) Worth Looking At Closely?

CEO & Director recently sold US$187k worth of stock

The Returns At Pediatrix Medical Group (NYSE:MD) Aren't Growing

Independent Director recently sold US$258k worth of stock

Pediatrix Medical Group, Inc. Appoints Sylvia Young as an Independent Director, Effective May 12, 2023

First quarter 2023 earnings: EPS misses analyst expectations

Pediatrix Medical Group (NYSE:MD) Has A Somewhat Strained Balance Sheet

Consensus EPS estimates fall by 11%

Is Now An Opportune Moment To Examine Pediatrix Medical Group, Inc. (NYSE:MD)?

Full year 2022 earnings: EPS misses analyst expectations

Pediatrix Medical Group Q4 2022 Earnings Preview

Is Pediatrix Medical Group (NYSE:MD) A Risky Investment?

Pediatrix: RCM Overhang Now Too Heavy, Revise To Hold

Return Trends At Pediatrix Medical Group (NYSE:MD) Aren't Appealing

Pediatrix Medical Group, Inc. Announces Executive Changes

Pediatrix appoints James Swift as chief executive officer

CEO & Director recently sold US$342k worth of stock

High number of new and inexperienced directors

Executive VP & Chief Operating Officer recently sold US$367k worth of stock

Consensus EPS estimates fall by 17%

Investor sentiment deteriorated over the past week

Why Pediatrix Medical Group, Inc. (NYSE:MD) Could Be Worth Watching

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Pediatrix Medical Group GAAP EPS of $0.37 misses by $0.11, revenue of $489.92M misses by $21.54M

Pediatrix Medical Group, Inc. to Report Q3, 2022 Results on Nov 03, 2022

Pediatrix: These 5 Graphs Suggest It's A Buy

Pediatrix Medical Group, Inc. Announces Executive Changes